子痫前期与溶血、肝酶升高、血小板减少综合征中的补体激活与调控
综述指出,正常妊娠存在一定补体激活,胎盘表达补体调节蛋白保护胎儿。子痫前期及HELLP综合征时补体激活增加、调控减弱,胎盘C5b-9沉积增加,刺激滋养细胞分泌sFlt-1。补体调节基因致病突变或缺失与疾病相关。C5b-9尿排泄与伴严重特征的子痫前期相关,可与其他妊娠高血压疾病鉴别。抑制末端补体通路可能有效,但需临床试验进一步评估。
要点
- 正常妊娠存在一定补体激活,胎盘补体调节蛋白抑制补体级联不同步骤以保护胎儿。
- 子痫前期及HELLP综合征时补体激活增加、调控减弱,胎盘C5b-9沉积增加。
- C5b-9刺激滋养细胞分泌sFlt-1,隔离VEGF与PlGF;补体调节基因突变或缺失与疾病相关。
核心结论
- 现有数据将子痫前期及HELLP综合征与末端补体通路激活增加相联系,部分病例可能受补体调节基因遗传改变影响。
- 抑制末端补体通路(可能通过C5阻断)可能是治疗子痫前期及HELLP综合征的有效策略,但该策略需在临床试验中进一步评估。
研究设计与样本
- 综述,总结补体系统在子痫前期及HELLP综合征中的激活与调控相关证据。
主要发现
- 正常妊娠可见一定补体激活,胎儿部分通过胎盘表达补体调节蛋白受到保护,这些蛋白抑制补体激活级联不同步骤。
- 子痫前期及HELLP综合征女性向补体激活增加和补体调控减弱偏移,胎盘C5b-9沉积增加,C5b-9是经典、凝集素和替代补体通路的末端效应物。
- C5b-9沉积刺激滋养细胞分泌可溶性fms样酪氨酸激酶-1,后者隔离血管内皮生长因子和胎盘生长因子。
- 子痫前期及HELLP综合征女性中检测到补体调节基因致病突变或缺失,这些改变易导致补体激活增加。
- 疾病发生前替代补体通路激活生物标志物升高;疾病活动期末端补体通路激活生物标志物升高;尿C5b-9排泄与伴严重特征的子痫前期相关,并与其他妊娠高血压疾病鉴别。
临床怎么用
- 作者认为抑制末端补体通路(可能通过C5阻断)可能是治疗子痫前期及HELLP综合征的有效策略,但需在临床试验中进一步评估。
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The complement system is critical to human health owing to its central role in host defense and innate immunity. During pregnancy, the complement system must be appropriately regulated to allow for immunologic tolerance to the developing fetus and placenta. Although some degree of complement activation can be seen in normal pregnancy, the fetus seems to be protected in part through the placental expression of complement regulatory proteins, which inhibit complement activation at different steps along the complement activation cascade. In women who develop preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome, there is a shift toward increased complement activation and decreased complement regulation. There is an increase in placental deposition of C5b-9, which is the terminal effector of classical, lectin, and alternative complement pathways. C5b-9 deposition stimulates trophoblasts to secrete soluble fms-like tyrosine kinase-1, which sequesters vascular endothelial growth factor and placental growth factor. Pathogenic mutations or deletions in complement regulatory genes, which predispose to increased complement activation, have been detected in women with preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. Before the disease, biomarkers of alternative complement pathway activation are increased; during active disease, biomarkers of terminal complement pathway activation are increased. Urinary excretion of C5b-9 is associated with preeclampsia with severe features and distinguishes it from other hypertensive disorders of pregnancy. Taken together, existing data link preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome with increased activation of the terminal complement pathway that, in some cases, may be influenced by genetic alterations in complement regulators. These findings suggest that the inhibition of the terminal complement pathway, possibly through C5 blockade, may be an effective strategy to treat preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome, but this strategy warrants further evaluation in clinical trials.
引用
- Burwick RM, Feinberg BB. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. Am J Obstet Gynecol. 2020. PMID: 32986992. doi:10.1016/j.ajog.2020.09.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。